Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
Year: 2026
Type: article
Study design: Clinical Trial
Source: The Lancet Haematology
Authors: Jeremy S Abramson, Susan Geyer, Sharmila Giri, Levi Pederson, Ann Hudson, Eric D Hsi, Neha Mehta-Shah, Patrick M Reagan, Richard L Deming, Richard F Little, Steven Gore, Shira N Dinner, Anusha Vallurupalli, Daniel J Landsburg, Brad Kahl, Jonathan W Friedberg, Nancy L Bartlett, John P Leonard
Institutions: Mass General Brigham, Mayo Clinic, Washington University in St. Louis, University of Rochester Medicine, University of Rochester, University of Iowa Health Care, National Cancer Institute, Northwestern University, University of Kansas Medical Center, Abramson Cancer Center, University of Pennsylvania, Weill Cornell Medicine
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Alliance Statistics and Data Management Center, ECOG-ACRIN Network Group Operations Center, G3231584006, Iowa-Wide Oncology Research Coalition (I-WORC), SWOG Network Group Operations Center of the NCTN, G4188603810, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, G580335595, Washington University/Siteman Cancer Center Lead Academic Site, NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1, G6705915398, Alliance for Clinical Trials in Oncology Operations Center
OpenAlex ID: W7204521331